Isomorphic Labs CEO Demis Hassabis with Endpoints' Andrew Dunn at the Financial Times' Global Pharma and Biotech Summit (courtesy Financial Times)
Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact
LONDON — Demis Hassabis is pursuing one of the boldest efforts of bringing AI into biotech, building out the Alphabet-backed startup Isomorphic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
